RESUMEN
OBJECTIVE: Intermittent stimulation of the left cervical vagus nerve trunk (VNS) with the NeuroCybernetic Prosthesis (NCP) is emerging as a novel adjunct in the management of medically refractory epilepsy. We review the safety and efficacy of VNS 1 year after completion of the E05 study, the largest controlled clinical trial of VNS to date. METHODS: One hundred and ninety-nine patients with intractable epilepsy and at least 6 complex partial or secondarily generalized seizures per month enrolled in a randomized, double-blinded, partial crossover trial of high versus low parameters of stimulation (E05). After 3 months, all patients received high stimulation during an open-label, nonblinded extension trial (XE5). Seizure frequency, adverse events and multiple physiologic variables were monitored at regular intervals. RESULTS: At 3 months, the mean reduction in seizure frequency among patients receiving high stimulation during E05 was 28%. Of the 199 subjects participating in this acute-phase trial, 195 continued in the long-term protocol. Among the latter patients, 21 subsequently exited the study due to lack of efficacy, and 2 others died from causes unrelated to VNS. Complete data were obtained for 164 of the remaining subjects. Using a declining N analysis, the mean and median reduction in seizure frequency at 15 months was 37 and 45%, respectively. A last visit carried forward analysis, which controls for dropouts and incomplete follow-up, yielded comparable results (34 and 45%, respectively), indicating little potential for selection bias. At 15 months, 39% of the subjects had a greater than 50% reduction in seizures, including 21% who had a greater than 75% reduction, and 2% have remained seizure free. Few serious adverse events, physiological perturbation or device failures were reported. CONCLUSIONS: The long-term multicenter safety, efficacy, feasibility and tolerability of VNS, as well as the durability of the NCP device have been confirmed. Unlike chronic therapy with antiepileptic medication, the efficacy of VNS is maintained during prolonged stimulation, and overall seizure control continues to improve with time.
Asunto(s)
Terapia por Estimulación Eléctrica , Epilepsia/terapia , Nervio Vago/fisiopatología , Adulto , Método Doble Ciego , Terapia por Estimulación Eléctrica/efectos adversos , Terapia por Estimulación Eléctrica/instrumentación , Terapia por Estimulación Eléctrica/métodos , Epilepsia Parcial Compleja/terapia , Femenino , Estudios de Seguimiento , Humanos , Masculino , Resultado del TratamientoRESUMEN
BACKGROUND: Chronic vagus nerve stimulation (VNS) continues to be evaluated as an adjunctive treatment for medically intractable seizures. A previous randomized controlled trial of 114 patients demonstrated a significant decrease in seizure frequency during 3 months of VNS at effective stimulation levels. OBJECTIVE: To evaluate the efficacy of 1 year of VNS therapy for the treatment of medically refractory partial seizures and the relationship between initial and long-term response. PATIENTS AND METHODS: All patients exiting the randomized controlled study of VNS for treatment of medically refractory partial seizures were offered indefinite treatment extension as part of an open-label trial. One hundred (88%) of 114 patients completed 12 months of VNS treatment at effective stimulation levels. Fourteen patients discontinued VNS treatment prior to 1 year, principally because of the treatment's lack of efficacy. These 14 patients were retained in the present analysis using an intent-to-treat approach. Antiepileptic drug use was monitored throughout the trial. Seizure frequency was analyzed in 4 sequential 3-month treatment periods. RESULTS: Compared with pretreatment baseline, there was a significant decrease in seizure frequency during each of the 3-month treatment periods. Seizure frequency was reduced by a median of 20% during the first 3 months of VNS treatment and by 32% during stimulation months 10 through 12. Response during the first 3 months of VNS treatment was a statistically significant predictor of response at months 10 through 12. The observed reduction in seizure frequency was not explained by overall changes in antiepileptic drug use. CONCLUSIONS: The results indicate that VNS remains an effective adjunctive therapy for medically refractory partial seizures over a period of at least 1 year. Response during the first 3 months of treatment is predictive of long-term response.
Asunto(s)
Epilepsias Parciales/terapia , Nervio Vago/fisiología , Adolescente , Adulto , Método Doble Ciego , Estimulación Eléctrica , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Vagus nerve stimulation (VNS) was shown to reduce seizure frequency in refractory epilepsy patients in two pilot studies. Based on these results, a multicenter, prospectively randomized, parallel, double-blind study of patients with refractory partial seizures was initiated. After a 12-week baseline period, identical vagus nerve stimulators were implanted and patients randomized to either a high or low 14-week VNS treatment paradigm. The primary objective was to demonstrate that high VNS (therapeutic parameters) was more effective in reducing partial seizure frequency than was low VNS (less or noneffective parameters). Patients continued receiving antiepileptic drugs (AEDs) with plasma concentrations held constant throughout the study. We report results of the first 67 patients to exit the 14-week acute phase. After 14 weeks of VNS, 31 patients receiving high VNS experienced a mean seizure frequency percentage reduction of 30.9%, which was statistically significant as compared with the mean seizure frequency percentage reduction of 11.3% in 36 patients receiving low VNS (p = 0.029, t test; p = 0.036, Wilcoxon rank-sum test). In addition to the significant intragroup p-values, mean seizure frequency percentage change reached statistical significance for high VNS (p < 0.001) but not low VNS (p = 0.072) as compared with baseline. Twelve of 31 (38.7%) patients receiving high VNS achieved at least 50% reduction in seizure frequency whereas 7 of 36 (19.4%) patients receiving low VNS experienced at least 50% reduction after 14 weeks. The implant procedure and VNS therapy were well tolerated. Our study confirmed the effectiveness of VNS as treatment for epilepsy patients with refractory partial seizures.
Asunto(s)
Terapia por Estimulación Eléctrica , Epilepsias Parciales/terapia , Nervio Vago/fisiología , Adolescente , Adulto , Anciano , Anticonvulsivantes/uso terapéutico , Niño , Terapia Combinada , Método Doble Ciego , Terapia por Estimulación Eléctrica/instrumentación , Terapia por Estimulación Eléctrica/métodos , Electrodos Implantados , Epilepsias Parciales/diagnóstico , Epilepsias Parciales/tratamiento farmacológico , Diseño de Equipo , Femenino , Estudios de Seguimiento , Humanos , Magnetismo , Masculino , Registros Médicos , Persona de Mediana Edad , Estudios Prospectivos , Prótesis e Implantes , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
Vagus nerve stimulation (VNS) has demonstrated a significant anticonvulsant effect in preclinical studies, in pilot studies in humans, and in the acute phase of a multicenter, double-blinded, randomized study. After completion of a 14-week, blinded, randomized study, with 31 receiving high (therapeutic) VNS and 36 receiving low (less or noneffective) VNS, 67 patients elected to continue in an open extension phase. During the extension phase, all 67 patients received high VNS. Seizure frequency during the 3-month treatment blocks was compared with a 12-week baseline. For both groups, all periods of high VNS demonstrated a significant decrease in seizure frequency (p < 0.01 level) as compared with baseline. For the 16-18-month period of VNS, data were available for 26 of the 31 patients randomized to high VNS. This group achieved a 52.0% mean seizure frequency percentage reduction as compared with baseline. For those converted from low to high VNS, data were available for 24 of the 36 patients at the 16-18-month time period. This group reported a mean seizure frequency percentage reduction of 38.1% as compared with baseline. No significant change in the safety/side effect profile was reported during long-term follow-up. The previously reported side effects of hoarseness/voice change, coughing, and paresthesia (sensation in neck and jaw) continued to occur during VNS. These side effects were well tolerated. During the follow-up period, 1 patient died of thrombotic thrombocytopenic purpura (TTP) and 5 patients discontinued treatment because of unsatisfactory efficacy.
Asunto(s)
Terapia por Estimulación Eléctrica/métodos , Epilepsias Parciales/terapia , Nervio Vago/fisiología , Adulto , Tos/etiología , Método Doble Ciego , Terapia por Estimulación Eléctrica/efectos adversos , Terapia por Estimulación Eléctrica/instrumentación , Electrodos Implantados , Epilepsias Parciales/diagnóstico , Epilepsias Parciales/epidemiología , Diseño de Equipo , Estudios de Seguimiento , Cefalea/etiología , Ronquera/etiología , Humanos , Parestesia/etiología , Pacientes Desistentes del Tratamiento , Prótesis e Implantes , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
We treated 14 patients with medically refractory partial seizures by stimulation of the vagus nerve in two single-blind pilot studies. Patients received stimulation through an implantable, programmable NeuroCybernetic Prosthesis, consisting of a pulse generator and a lead-electrode assembly. The mean reduction in seizure frequency after 14 to 35 months of vagal stimulation was 46.6%. Of the 14 patients, five (35.7%) had a 50% or greater reduction in seizure frequency. Two patients, one of whom had had 10 to 100 seizures per day before stimulation, have been seizure-free for over 1 year. Adverse events were primarily limited to initial hoarseness and a tingling sensation at the electrode site in the neck when the device was activated. Most patients tolerated the device and stimulation well. There were no permanent adverse events. Some cases of medically refractory partial seizures are improved by vagal stimulation.
Asunto(s)
Terapia por Estimulación Eléctrica/métodos , Epilepsia/terapia , Nervio Vago/fisiopatología , Adolescente , Adulto , Anticonvulsivantes/uso terapéutico , Terapia Combinada , Terapia por Estimulación Eléctrica/efectos adversos , Terapia por Estimulación Eléctrica/instrumentación , Electrodos Implantados , Epilepsia/fisiopatología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Seguridad , Método Simple CiegoRESUMEN
Over 100 patients have been treated for partial epilepsy using a NeuroCybernetic Prosthesis System (NCP). The NCP System is comprised of an implantable pulse generator, an implantable bipolar stimulating lead, and an external communication system. The lead delivers electrical impulses from the NCP Generator to the vagus nerve, and includes a connector end that plugs into the generator, a silicone insulated lead body, and the helical electrode array that attaches to the nerve. The surgical implantation technique has a significant impact on lead reliability and performance. The lead electrode has performed well to date. Modifications to further improve reliability have been implemented. Clinical experience, case history examples, and voltage measurements are examined. The lead electrode is an important component of the overall system and plays a significant part in the success of vagus nerve stimulation therapy.
Asunto(s)
Terapia por Estimulación Eléctrica/instrumentación , Epilepsias Parciales/terapia , Prótesis e Implantes , Nervio Vago/fisiología , Adolescente , Adulto , Electrodos Implantados , Diseño de Equipo , Falla de Equipo , Humanos , Masculino , Nervio Vago/cirugíaRESUMEN
Vagus nerve stimulation for the treatment of epilepsy has been studied in medically refractory patients with partial seizures in a randomized, blinded, parallel study. After a 3-month baseline period, the patients were implanted with the Neurocybernetic Prosthesis (NCP) system consisting of the NCP Generator and the Bipolar Vagal Stimulation Lead. Two stimulation paradigms were used, HIGH, which delivers what is considered to be optimal stimulation parameters and LOW, which is considered to be less or noneffective. The system and vagus nerve stimulation were well tolerated and few adverse events have been attributed to either. One patient experienced a period of direct current to the nerve due to a generator malfunction. This results in paralysis of the left vocal cord. Efficacy analysis on the first 37 patients to complete the controlled portion of the study has shown that the patients in the HIGH group experienced a mean reduction in seizure frequency of 33.3% and patients in the LOW group experienced a mean reduction in seizure frequency of 8.4%. The difference between the groups is statistically significant with a P value of 0.025. Analysis of seizure duration and intensity does not show any significant change. Ratings of the patient's overall condition by the patient, investigator, and companion as a measurement of "quality of life" also show improvement in the HIGH group. The results of this interim study demonstrate that vagus nerve stimulation is a safe and effective method of treating partial epileptic seizures.
Asunto(s)
Terapia por Estimulación Eléctrica/instrumentación , Epilepsias Parciales/terapia , Epilepsia Parcial Compleja/terapia , Prótesis e Implantes , Nervio Vago/fisiología , Adulto , Anticonvulsivantes/uso terapéutico , Electrodos Implantados , Epilepsias Parciales/psicología , Epilepsia Parcial Compleja/psicología , Femenino , Humanos , Masculino , Calidad de VidaRESUMEN
The neurocybernetic prosthesis system (NCP) is an implantable, multiprogrammable pulse generator that delivers constant current electrical signals to the vagus nerve for the purpose of reducing the frequency and severity of epileptic seizures. The signals are delivered on a predetermined schedule, or may be initiated by the patient with an external magnet. The device is implanted in a subcutaneous pocket in the chest just below the clavicle, similar to pacemaker placement. The stimulation signal is transmitted from the prosthesis to the vagus nerve through a lead connected to an electrode which is a multi-turn silicone helix, with a platinum band on the inner turn of one helix. The prosthesis can be programmed with any IBM- compatible personal computer using NCP software and a programming wand.
Asunto(s)
Cibernética/instrumentación , Terapia por Estimulación Eléctrica/instrumentación , Epilepsia/terapia , Prótesis e Implantes , Nervio Vago/fisiología , Suministros de Energía Eléctrica , Electrodos Implantados , Electrónica Médica/instrumentación , Epilepsia/tratamiento farmacológico , Diseño de Equipo , Humanos , Programas InformáticosRESUMEN
The neurocybernetic prosthesis (Cyberonics, Inc.) is an implantable, multiprogrammable pulse generator that delivers constant current electrical signals to the vagus nerve for the purpose of reducing the frequency and/or severity of epileptic seizures. The device is implanted in a subcutaneous chest pocket just below the clavicle, similar to cardiac pacemaker placement. The stimulation signal is transmitted from the prosthesis to the vagus nerve through a stimulation lead. The prosthesis can be programmed using any IBM-compatible personal computer with programming software and a programming wand. The electrodes used in the first group of patients were found to break at an unacceptable rate. Design modifications appear to have resolved this problem.